In clinical trials3,4,5Evidence: Smaller human trialsMetabolic and weight

Avexitide3

Key takeaway

Avexitide is a synthetic peptide, the 9-39 fragment of exendin, that blocks the GLP-1 receptor, according to trial investigators.3,4 It is being developed for dangerously low blood sugar after meals in people who have had bariatric surgery. In a small placebo-controlled crossover trial of 18 women, it raised the lowest blood sugar after a test meal by about a fifth to a quarter.4 No FDA approval is reported in the sources reviewed here, and avexitide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,8

Avexitide at a glance

What it isA synthetic 31-amino-acid peptide amide, exendin (9-39), recorded as avexitide acetate in FDA’s substance registry; trial authors describe it as a GLP-1 receptor antagonist.3,4
FDA statusNot FDA-approved. None of the sources reviewed here reports an approval of avexitide.3,4
Human evidenceSmall trials in post-bariatric hypoglycemia: a placebo-controlled crossover trial in 18 women and a 2026 Phase 2b study in 16 completers without a placebo group.4,5
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is avexitide?

Avexitide is a synthetic peptide matching amino acids 9 to 39 of exendin-3, a lizard peptide, and ending in an amide. FDA’s substance registry records it as avexitide acetate, with exendin (9-39) amide acetate among its names.3

How is avexitide thought to work?

The PREVENT investigators describe avexitide as a GLP-1 receptor antagonist. After some stomach surgeries, the gut releases excess GLP-1 after meals, which can drive insulin too high and blood sugar too low; blocking the receptor is meant to blunt that.4,5

What do human studies show?

In PREVENT, 18 women with post-bariatric hypoglycemia received placebo for 14 days and then avexitide for two further periods in randomized sequence. Compared with placebo, avexitide raised the lowest blood sugar during a test meal by 21% and 26% and lowered peak insulin.4

In a 2026 Phase 2b study of 16 completers after bariatric and other upper stomach surgeries, avexitide reduced the rate of significant low blood sugar events by about half compared with a run-in period, with no serious adverse events reported. The study had no placebo group.5

ClinicalTrials.gov lists a Phase 3 trial of avexitide in post-bariatric hypoglycemia (NCT06747468) as active, not recruiting, in its August 24, 2026 record.1

What the evidence base contains

  • Controlled human trial PREVENT: a multicenter, randomized, placebo-controlled crossover Phase 2 trial in 18 women with post-bariatric hypoglycemia (2021).4
  • Small, short, or incompletely reported human study A 2026 Phase 2b study comparing avexitide with a run-in period in 16 completers after bariatric or other upper gastrointestinal surgery, without a placebo group.5

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is avexitide FDA-approved?

None of the sources reviewed here reports an approval of avexitide by FDA. The 2021 PREVENT report states that there was no approved therapy for post-bariatric hypoglycemia.3,4

Avexitide remains in clinical trials: its Phase 3 registration (NCT06747468) is listed as active, not recruiting, in its August 24, 2026 record.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list avexitide.6

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Avexitide is not among them.7,8

Timeline

  1. The PREVENT crossover trial of avexitide in 18 women is published.4
  2. A Phase 2b study of avexitide after bariatric and other upper gastrointestinal surgeries is published.5

What is still unknown?

Whether its benefits hold in larger and longer trials: the published studies enrolled fewer than 20 people each and lasted weeks.4,5

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Avexitide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Avexitide are a bounded selection, not every registration or paper about Avexitide. For the years before Avexitide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Avexitide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Avexitide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. Small trials, including a placebo-controlled crossover trial in 18 women, found higher blood sugar lows and fewer hypoglycemia events. Avexitide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Avexitide?

In clinical trials; not FDA-approved. Small trials, including a placebo-controlled crossover trial in 18 women, found higher blood sugar lows and fewer hypoglycemia events. Avexitide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
3
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Avexitide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

3Selected dated records
9Connected citations
3Populated source years2022–2026
1/4Record lanes present

Registered human studies

Trial composition

3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.

PhasesPhase 2 2Phase 3 1
Status at observationCompleted 2Active, not recruiting 1

PubMed bibliography

Publication composition

0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
3

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 3 dated records

Research hub

Explore the Avexitide evidence record

Open all 3 records →
3Dated records
1Evidence type
3Cited public sources
3Source years

Change ledger

Recently changed for Avexitide

Open all 3 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT03373435

PeptideScanner retained ClinicalTrials.gov record NCT03373435 at 2026-11-16T01:46:44.871Z. Its registry update date was 2022-07-18, and PeptideScanner's reviewed identity mapping was avexitide.

PeptideScanner change date
November 16, 2026
Cited source date
July 18, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04652479

PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.

PeptideScanner change date
November 16, 2026
Cited source date
June 9, 2023
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06747468

PeptideScanner retained ClinicalTrials.gov record NCT06747468 at 2026-11-16T01:46:44.871Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was avexitide.

PeptideScanner change date
November 16, 2026
Cited source date
August 24, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Avexitide

Open the full research atlas →
ClinicalTrials.gov3

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06747468Registry update August 24, 2026 · current at observation
  2. NCT04652479Registry update June 9, 2023 · completed at observation
  3. NCT03373435Registry update July 18, 2022 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span July 18, 2022 to August 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3,6
  • U.S. Department of Health and Human Services7
Dated updates connected to this profile · 3

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06747468↗

    PeptideScanner retained ClinicalTrials.gov record NCT06747468 at 2026-11-16T01:46:44.871Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was avexitide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04652479↗

    PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT03373435↗

    PeptideScanner retained ClinicalTrials.gov record NCT03373435 at 2026-11-16T01:46:44.871Z. Its registry update date was 2022-07-18, and PeptideScanner's reviewed identity mapping was avexitide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT06747468 · retained source version 2026-08-24:84cd79c4a61d08699f69791888aadfddd291dd460e6607eabfdf1782cd3756f1 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT03373435 · retained source version 2022-07-18:9d51eeca0c4374ca2375e19de4368370e58abd881c8ecc85ea87eba68eb09544 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Avexitide acetate substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗

    The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026

  5. 5
    Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗

    Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026

  6. 6
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026